

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of)	
)	FOR: METHODS FOR DIAGNOSING,
Joseph L. WITZTUM et al.)	IMAGING AND TREATING
)	ATHEROSCLEROTIC DISEASE
Serial No.: Unknown)	
based on 09/699,131)	Group
filed on October 26, 2000)	Art Unit: Unknown
)	
Filed: Herewith)	

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Mail Stop DD
Commissioner for Patents
P. O. Box 1450
Alexandria VA 22313-1450

Dear Examiner:

Applicants submit herewith references of which they are aware, which they believe may be material to patentability of the invention disclosed and claimed in the new patent application filed herewith and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.


Applicants are submitting herewith copies of the references which are set forth on the attached Form PT/SB/08A. As all relevant parts of the references are in the English language, no explanation of the references is provided herein.

Further, while the references provided in this Information Disclosure Statement may be material to patentability pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specifically designated as such.

Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

Respectfully submitted,

Dated: November 11, 2003

By: 
Colleen J. McKiernan
Agent for Applicants
Registration No. 48,570

BROWN MARTIN HALLER & McCLAIN LLP
1660 Union Street
San Diego, California 92101

Telephone: (619) 238-0999
Facsimile: (619) 238-0062

Docket No.: 6627-P0045C

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/699,131
				Filing Date	October 26, 2000
				First Named Inventor	Joseph L. Witztum
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket Number	6627-PA0045
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	4	Hörkkö, S., Miller, E., Dudl, E., et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized LDL. <i>J. Clin. Invest.</i> 1996;98:815-825.			
	5	Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. <i>Science.</i> 1989;246:1275-1281.			
	6	Palinski, W., Hörkkö, S., Miller et al: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apo E-deficient mice. Demonstration of epitopes of oxidized LDL in human plasma. <i>J. Clin. Invest.</i> 1996;98:800-814.			
	7	Shaw, P.X., Hörkkö, S., Chang, M-K, Curtiss, L.K., Palinski, W., Silverman, G.J. and Witztum, J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. <i>J. Clin. Invest.</i> 105:1731-40, 2000.			
	8	Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, Mab, identifies native atherosclerotic lesions in vivo. <i>J Nucl Cardiol.</i> 1999;6:41-53.			
	9	Wu CC, Chang SW, Chen MS, Lee YT. Early change of vascular permeability in hypercholesterolemic rabbits. <i>Arterioscler Thromb Vasc Biol.</i> 1995;15:529-533.			
Examiner				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

52

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/699,131
Filing Date	10/26/2000
First Named Inventor	Joseph L. Witztum
Art Unit	1641
Examiner Name	Lisa V. Cook
Attorney Docket Number	6627-PA0045

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	Libby, P. et al. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine, Vol. 8, No. 11, 1257-1262, Nov. 2002	
	11	Narula, J., et al. Strategic targeting of atherosclerotic lesions. Journal of Nuclear Cardiology, Part 1, pp. 81-90, Jan./Feb. 1999	
	12	Strauss, H.W. Imaging of atherosclerosis – A worthy challenge. Journal of Nuclear Cardiology, Vol. 3, No. 3, pp. 278-280, May/June 1996	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T : Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.